Blinkbio Inc., of Jupiter, Fla., entered a collaboration agreement with Janssen Pharmaceuticals Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, in the discovery research area, in order to accelerate the optimization of prototype leads discovered in the company's self-assembling dimer program targeting the inhibition of Protein-Protein Interactions.